R & D Daily: anstelai invests heavily in general car / tcr-t cell therapy

Estella has invested heavily in general car / tcr-t cell therapy; 204 varieties have passed / deemed to pass the consistency evaluation; Keya medical artificial intelligence medical imaging products have been approved; Estella cooperates with adaptimmune to develop car-t and TCR therapy We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel On the 14th, Japanese pharmaceutical company Astaire reached a US $897.5 million cooperation agreement with British adaptive therapeutics company to jointly develop and commercialize stem cell-derived allogeneic T-cell therapy On May 15, Keya medical "deep pulse score" obtained the first registration certificate of artificial intelligence class III medical devices issued by the State Drug Administration and was approved for clinical application Clovis oncology recently announced that the FDA of the United States has accepted an application for a supplementary new drug targeting the anticancer drug rubraca and granted priority review Rubrca was used as a single drug therapy in adult patients with BRCA1 / 2 mutation, recurrent and metastatic castration resistant prostate cancer On May 15, Bristol Myers Squibb announced that the U.S FDA has accepted a supplementary biological product license application (SBLA) submitted by it and granted priority review, and the prescription drug user fee law is May 15, 2020 Recordati recently announced that the European Commission (EC) has approved the marketing license of the orphan drug product isturia ® (osilodostat), which is used to treat adult endogenous Cushing's syndrome Recently, through its wholly-owned subsidiary universal cells, astralas has reached an agreement with adaptimmune to jointly develop and commercialize allogeneic T-cell therapy, which will bring new stem cell sources to cancer patients.